Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Payables: 2010-2025

Historic Payables for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $30.2 million.

  • BIO-TECHNE's Payables fell 4.44% to $30.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.2 million, marking a year-over-year decrease of 7.47%. This contributed to the annual value of $25.3 million for FY2025, which is 33.34% down from last year.
  • BIO-TECHNE's Payables amounted to $30.2 million in Q3 2025, which was up 19.15% from $25.3 million recorded in Q2 2025.
  • In the past 5 years, BIO-TECHNE's Payables ranged from a high of $38.0 million in Q2 2024 and a low of $24.1 million during Q4 2022.
  • Moreover, its 3-year median value for Payables was $30.2 million (2025), whereas its average is $30.1 million.
  • As far as peak fluctuations go, BIO-TECHNE's Payables skyrocketed by 47.86% in 2024, and later tumbled by 33.34% in 2025.
  • BIO-TECHNE's Payables (Quarterly) stood at $26.8 million in 2021, then fell by 9.93% to $24.1 million in 2022, then skyrocketed by 30.76% to $31.5 million in 2023, then rose by 5.10% to $33.1 million in 2024, then decreased by 4.44% to $30.2 million in 2025.
  • Its Payables stands at $30.2 million for Q3 2025, versus $25.3 million for Q2 2025 and $31.6 million for Q1 2025.